Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 62, Issue 3, pp 551–557 | Cite as

Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients

  • Kazuhiro Ozawa
  • Hironobu Minami
  • Hitoshi SatoEmail author
Short Communication

Abstract

Purpose

Fever occurring in a neutropenic patient remains a common life-threatening complication of cancer chemotherapy, and febrile neutropenia (FN) is recognized as a dose-limiting factor (DLF) in cancer chemotherapy. The aim of this study is to evaluate the significant covariate associated with the risk of FN occurrence in Japanese patients.

Methods

A stepwise logistic regression was conducted using data from Japanese cancer patients treated with docetaxel. Based on those results, an equation was established which predicts the probability of FN occurrence.

Results

From the result of a stepwise multivariate logistic regression analysis, performance status factor (PS*), which is set to 1 if performance status factor is 2 or 3, and to 0 otherwise and area under the plasma concentration versus time curve (AUC) were selected as covariates significantly associated (p < 0.05) with FN occurrence. The obtained equation to predict the probability (P) of docetaxel-induced FN occurrence is P = 1/[1 + exp{−(1.29 × AUC + 1.41 × PS* −3.52)}]. A receiver operating characteristic (ROC) curve analysis revealed that the best cut-off value of FN probability to differentiate between the presence and absence of FN was 0.61.

Conclusions

An equation was developed to predict the probability of FN occurrence for Japanese patients treated with docetaxel. It was found that FN may not occur when the probability of FN occurrence calculated by the predictive equation is less than 0.61. Therefore, the predictive equation for FN occurrence may be used for selecting the appropriate dose to avoid the occurrence of FN.

Keywords

Docetaxel Febrile neutropenia Logistic regression analysis Neutrophils Japanese cancer patients 

Notes

Acknowledgments

This study was supported in part by Grants-in-Aid from the Ministry of Health and Welfare, Japan.

References

  1. 1.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–339PubMedGoogle Scholar
  2. 2.
    Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332PubMedCrossRefGoogle Scholar
  3. 3.
    Smith GM, Leyland MJ, Farrell ID, Geddes AM (1988) A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients. J Antimicrob Chemother 21:647–655PubMedCrossRefGoogle Scholar
  4. 4.
    Klastersky J (1993) Febrile neutropenia. Curr Opin Oncol 5:625–632PubMedCrossRefGoogle Scholar
  5. 5.
    Rubenstein EB, Rolston KV (1995) Outpatient treatment of febrile neutropenic patients with cancer. Eur J Cancer 31A:2–4PubMedCrossRefGoogle Scholar
  6. 6.
    Kojima A, Shinkai T, Soejima Y, Okamoto H, Eguchi K, Sasaki Y, Tamura T, Oshita F, Ohe Y, Saijo N (1994) A randomized prospective study of imipenem-cilastatin with or without amikacin as an empirical antibiotic treatment for febrile neutropenic patients. Am J Clin Oncol 17:400–404PubMedCrossRefGoogle Scholar
  7. 7.
    Carlson JW, Fowler JM, Saltzman AK, Carter JR, Chen MD, Mitchell SK, Dunn D, Carson LF, Adcock LL, Twiggs LB (1994) Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol. Gynecol Oncol 55(Pt 1):415–420PubMedCrossRefGoogle Scholar
  8. 8.
    Sjőstrőm J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lőnn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjővall M, Wist E, Valvere V, Anderson H, Bergh J (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35(8):1194–1201PubMedCrossRefGoogle Scholar
  9. 9.
    Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12):2354–2362. Erratum in: J Clin Oncol. 2004 Jan 1 22(1): 209PubMedGoogle Scholar
  10. 10.
    Vasey PA (2003) Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J Clin Oncol 21(10 Suppl):136s–144sPubMedCrossRefGoogle Scholar
  11. 11.
    Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR (1996) Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14(5):1672–1678PubMedGoogle Scholar
  12. 12.
    Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70(2):380–383PubMedGoogle Scholar
  13. 13.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512Google Scholar
  14. 14.
    Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187–196PubMedGoogle Scholar
  15. 15.
    Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T, Biron P (1996) Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14(2):636–643PubMedGoogle Scholar
  16. 16.
    Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D (2000) A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 37(3–4):351–360PubMedGoogle Scholar
  17. 17.
    Ozawa K, Minami H, Sato H (2007) Population pharmacokinetic-pharmacodynamic analysis for the time courses of docetaxel-induced neutropenia in Japanese cancer patients. Cancer Sci 98:1985–1992Google Scholar
  18. 18.
    Vergniol J, Bruno R, Montay G, Frydman A (1992) Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582:273–278PubMedCrossRefGoogle Scholar
  19. 19.
    Efron B, Tibshirani R (1986) Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1:54–75CrossRefGoogle Scholar
  20. 20.
    Harrell Jr FE, Lee KL, Mark DB (1996) Mulitvariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Kazuhiro Ozawa
    • 1
  • Hironobu Minami
    • 2
    • 3
  • Hitoshi Sato
    • 1
    Email author
  1. 1.Department of Clinical and Molecular Pharmacokinetics/Pharmacodynamics, School of Pharmaceutical SciencesShowa UniversityTokyoJapan
  2. 2.The Division of Oncology/HematologyNational Cancer Center Hospital EastChibaJapan
  3. 3.Medical Oncology, Department of MedicineKobe University Hospital and Graduate School of MedicineHyogoJapan

Personalised recommendations